Skip to navigation Skip to content

Severe asthma (SA) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051136

This document outlines details of PBS-subsidised biological medicines for patients with severe asthma (SA).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

On this page:

Severe asthma (SA) quick reference - paediatric (patients aged 6 to 11 years old)

Severe asthma (SA) quick reference - adolescent and adult (patients aged 12 years or older)

Severe asthma (SA) quick reference - paediatric (patients aged 6 to 11 years old)

Table 1

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB188 form	Written S100: omalizumab	Yes	OPA	Must be treated by a: paediatric respiratory physician clinical immunologist allergist paediatrician, in consultation with a respiratory physician, or general physician in consultation with a respiratory physician	No
Continuing	Telephone Electronic S100: omalizumab	No	OPA	Must be treated by a: paediatric respiratory physician clinical immunologist allergist paediatrician in consultation with a respiratory physician, or general physician in consultation with a respiratory physician	Yes
Balance of supply	Telephone Electronic S100: omalizumab	No	OPA	Must be treated by a: paediatric respiratory physician clinical immunologist allergist paediatrician in consultation with a respiratory physician general physician in consultation with a respiratory physician	Yes

Severe asthma (SA) quick reference - adolescent and adult (patients aged 12 years or older)

Table 2

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial or recommencement after a break (>12 months) PB075 form	Written S100: benralizumab dupilumab mepolizumab omalizumab	Yes	OPA	Must be treated by a: respiratory physician clinical immunologist allergist, or general physician experienced in the management of patients with severe asthma	No
Continuing PB076 form	Written S100: benralizumab dupilumab mepolizumab Note: patients on dupilumab 300mg can lower the dose to 200mg as continuing treatment.	No	OPA	Must be treated by a: respiratory physician clinical immunologist allergist, or general physician experienced in the management of patients with severe asthma	No
Continuing	Telephone Electronic S100: omalizumab	No	OPA	Must be treated by a: respiratory physician clinical immunologist allergist, or general physician experienced in the management of patients with severe asthma	Yes
Change PB285 form	Written S100: benralizumab dupilumab mepolizumab omalizumab	No	OPA	Must be treated by a: respiratory physician clinical immunologist allergist, or general physician experienced in the management of patients with severe asthma	No
Balance of supply	Telephone Electronic S100: benralizumab mepolizumab omalizumab	No	OPA	Must be treated by a: paediatric respiratory physician clinical immunologist allergist paediatrician, or general physician experienced in the management of patients with severe asthma	Yes